Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

Clinical trial NCT06699498 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06699498
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Head and Neck Squamous Cell Carcinoma Neoadjuvant Therapy PD-L1 Anlotinib

Start date: 2024-12-03
Primary completion: 2025-12-01
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.